Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Safety and performance of an anti-microbial vascular graft in the treatment of aneurysmal and occlusive disease of the abdominal aorta.
The purpose of this multi center, single arm study is to demonstrate the safety and performance of the Second Generation Anti-Microbial (InterGard Synergy) vascular graft in the treatment of aneurismal and occlusive diseases of the abdominal aorta.
The primary endpoint is the assessment of primary and secondary graft patency. The secondary endpoints were the assessment of adverse events and the assessment of triclosan and silver contents in the serum over the time.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intergard Synergy Graft | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intergard Synergy Graft | Device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Primary Graft Patency | Defined as uniterrupted flow with no interventions. Follow-up timeframes - 1, 6, 12, 24, and 36 months | Up to 36 months |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary endpoint - assessment of AEs | Follow-up timeframes - 1, 6, 12, 24, and 36 months | Up to 36 months |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary endpoint - levels of silver and triclosan | Serum levels prior to surgery, 1 day post-implant, discharge and 30 days | Up to 30 days |
Inclusion Criteria:
Patient aged 18-85 years
Patient presenting with an aorto-iliac occlusion (obstruction of flow) or stenosis, or aorto-iliac aneurysm and eligible for a revascularization with a bifurcated graft
Exclusion Criteria:
Patient treated as an emergency
Patient included in another investigation
Patient pregnant or lactating or woman of childbearing potential
Patient with a known allergy to the material device used (collagen, triclosan, silver)
Patient with previous aorto-iliac bypass or replacement
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jean-Baptiste Ricco, MD | CHU La Milétrie | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHRU | Angers | France | ||||
| CHU Jean Minjoz |
Not provided
| ID | Term |
|---|---|
| D017544 | Aortic Aneurysm, Abdominal |
| ID | Term |
|---|---|
| D001014 | Aortic Aneurysm |
| D000783 | Aneurysm |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Besançon |
| France |
| CHU Dupuytren | Limoges | France |
| Hôpital Edouard Herriot | Lyon | France |
| Hôpital G. et R. Laennec | Nantes | France |
| Hôpital Pompidou | Paris | France |
| CHU La Milétrie | Poitiers | France |
| Krankenhaus Nordwest | Frankfurt | Germany |
| D001018 |
| Aortic Diseases |